H.C. Wainwright raised the firm’s price target on Barinthus Biotherapeutics (BRNS) to $4 from $3 and keeps a Buy rating on the shares following the Q3 report.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Biotherapeutics Reports Q3 2025 Earnings
- Barinthus Biotherapeutics reports Q3 EPS (36c) vs (21c) last year
- Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial
- Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
- Barinthus Bio, Clywedog enter definitive merger agreement